Celiprolol, a vasodilatory β-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice

Circulation

Volumn 110, Issue 6, 2004, Pages 692-699

  Liao, Yulin ^a   Asakura, Masanori ^a   Takashima, Seiji ^a   Ogai, Akiko ^b   Asano, Yoshihiro ^a   Shintani, Yasunori ^a   Minamino, Tetsuo ^a   Asanuma, Hiroshi ^a   Sanada, Shoji ^a   Kim, Jiyoong ^b   Kitamura, Soichiro ^b   Tomoike, Hitonobu ^b   Hori, Masatsugu ^a   Kitakaze, Masafumi ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Heart failure; Hypertrophy; Nitric oxide; Receptors, adrenergic, beta

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CELIPROLOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENALINE; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART WEIGHT; LUNG WEIGHT; MORBIDITY; MORTALITY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BLOCKING;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOMEGALY; CELIPROLOL; CELLS, CULTURED; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; ENZYME INDUCTION; FIBROSIS; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; HYPERTROPHY; ISOPROTERENOL; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PHENYLEPHRINE; PRESSURE; RATS; RECEPTORS, ADRENERGIC, BETA-1; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VASODILATOR AGENTS;

EID: 4043134412     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000137831.08683.E1     Document Type: Article

References (38)

1. Friddle CJ, Koga T, Rubin EM, et al. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci USA. 2000;97:6745-6750.
2. Morisco C, Zebrowski DC, Vatner DE, et al. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol. 2001;33:561-573.
3. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997;95:2007-2014.
4. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812-818.
5. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001;104:1286-1291.
6. Linz W, Wohlfart P, Scholkens BA, et al. Interactions among ACE, kinins and NO. Cardiovasc Res. 1999;43:549-561.
7. Takemoto M, Node K, Nakagami H, et al. Stalins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
8. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868-873.
9. Ogita H, Node K, Liao Y, et al. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension. 2004;43:237-242.
10. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747-2752.
11. Asanuma H, Node K, Minamino T, et al. Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol. 2003;41:499-505.
12. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension. 2003;1:963-967.
13. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40.
14. Liao Y, Ishikura F, Beppu S, et al. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol. 2002;282:H1703-H1708.
15. Liao Y, Takashima S, Asano Y, et al. Activation of adenosine A, receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res. 2003;93:759-766.
16. Kurisu S, Ozono R, Oshima T, et al. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension. 2003;41:99-107.
17. Kitakaze M, Node K, Minamino T, et al. Role of nitric oxide in regulation of coronary blood flow during myocardial ischemia in dogs. J Am Coll Cardiol. 1996;27:1804-1812.
18. Kobayashi N, Mita S, Yoshida K, et al. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 via NF-κB induced by oxidative stress. Hypertension. 2003;42:1004-1013.
19. Asano Y, Takashima S, Asakura M, et al. Lamr1 functional retroposon causes right ventricular dysplasia in mice. Nat Genet. 2004;36:123-130.
20. Silvagno F, Xia H, Bredt DS. Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. J Biol Chem. 1996;271:11204-11208.
21. Yu CM, Fung PC, Chan G, et al. Plasma nitric oxide level in heart failure secondary to left ventricular diastolic dysfunction. Am J Cardiol. 2001;88:867-870.
22. Tonduangu D, Hittinger L, Ghaleh B, et al. Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs. Circulation. 2004;109:114-119.
23. Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation. 1999;99:2113-2117.
24. Agnoletti L, Curello S, Bachetti T, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-α. Circulation. 1999;100:1983-1991.
25. Kobayashi N, Mori Y, Nakano S, et al. Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 2001;19:795-801.
26. Jones SP, Greer JJ, van Haperen R, et al. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA. 2003;100:4891-4896.
27. Balligand JL, Kelly RA, Marsden PA, et al. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 1993;90:347-351.
28. Hare JM, Keaney JF Jr, Balligand JL, et al. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest. 1995;95:360-366.
29. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
30. Jaffrey SR, Snyder SH. PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science. 1996;274:774-777.
31. Hemmens B, Woschitz S, Fitters E, et al. The protein inhibitor of neuronal nitric oxide synthase (PIN): characterization of its action on pure nitric oxide synthases. FEBS Lett. 1998;430:397-400.
32. Patel KP, Zhang K, Zucker IH, et al. Decreased gene expression of neuronal nitric oxide synthase in hypothalamus and brainstem of rats in heart failure. Brain Res. 1996;734:109-115.
33. Dixon LJ, Morgan DR, Hughes SM, et al. Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation. 2003;107:1725-1728.
34. Zhang K, Li YF, Patel KP. Blunted nitric oxide-mediated inhibition of renal nerve discharge within PVN of rats with heart failure. Am J Physiol. 2001;281:H995-H1004.
35. Hirooka Y, Shigematsu H, Kishi T, et al. Reduced nitric oxide synthase in the brainstem contributes to enhanced sympathetic drive in rats with heart failure. J Cardiovasc Pharmacol. 2003;42(suppl 1):S111-S115.
36. Witchitz S, Cohen-Solal A, Dartois N, et al. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group. Am J Cardiol. 2000;85:1467-1471.
37. Pietila M, Malminiemi K, Huupponen R, et al. Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. Eur J Heart Fail. 2000;2:81-90.
38. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-1446.